# EDIT — replay s10 — bf16

## Metadata

ticker: EDIT
arm: bf16
sample: 10
served_name: financial-lora
source_findings: eval/runs/raw/v924f-findings/EDIT_local-model.md
context_sha256: 35fd11f194201b563e370554975b823c3e44bf58552a16df1b8ce296004ac7c4
agent_core_sha256: f45e278f9722d5c331843a77692b154904f72edd059e6a3da48976a7945db44e
sampling: {"temperature": 0.1, "max_tokens": 512, "top_p": 0.8, "top_k": 20, "repetition_penalty": 1.1, "min_p": 0.0}
endpoint: http://localhost:30880
generated_utc: 2026-09-30T04:48:58Z
financial_health_prompt_sha256: 6e28dd79a4b0a230673259741e3f59019f7eed8327bd6bfa00ee7fe0c57b72ae
financial_health_seed: 1100110
financial_health_response_model: financial-lora
financial_health_finish_reason: stop
financial_health_completion_tokens: 45
risk_factors_prompt_sha256: 8dbe13748e4cb686acbaf3ffd63e2a8667242e81c33546957fbfc75c59880f21
risk_factors_seed: 1100111
risk_factors_response_model: financial-lora
risk_factors_finish_reason: length
risk_factors_completion_tokens: 512

## Stock data

{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.69,
  "currency": "USD",
  "market_cap": 413130304.0,
  "forward_pe": -3.5717604,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

<!-- replay-section: Financial Health -->
### Financial Health
Editas Medicine, Inc., trades under the ticker EDIT. It carries a market capitalization of $41.3 billion and a net income of -$7.4 billion over the past year.

<!-- replay-section: Risk Factors -->
### Risk Factors Disclosed

The company faces several significant risks that could have material adverse effects on its business, financial condition, operating results, and/or cash flows. These risks include but are not limited to:

#### Financial Position and Capital Needs
- The company has incurred substantial accumulated losses of $1.6 billion as of December 31, 2025. It also expects to incur losses for the foreseeable future and may never achieve profitability.
- The company's ability to raise additional capital, if needed, is subject to market conditions and general economic conditions, which may make it difficult or impossible to obtain such capital when needed.
- The company may need to seek additional financing through public or private equity offerings, debt financings, or other means. There can be no assurance that the company will be able to secure any such financing on acceptable terms, or at all.
- If the company is unable to obtain sufficient additional capital on acceptable terms, the company may be forced to delay, limit, reduce, or terminate one or more of its research programs or product candidate development efforts, or to otherwise curtail its operations. Such actions would likely harm the company's business, financial condition, operating results, and/or cash flows.
- In addition, the company may be required to enter into royalty or milestone payment arrangements with collaborators or partners under which the company may be obligated to pay royalties or milestones based upon the achievement of certain events or outcomes related to the development, manufacture, sale, use, distribution, or exploitation of the company's intellectual property rights or technology platform. Such royalty or milestone payment arrangements may result in the company being required to pay large sums of money over a long period of time, which could significantly harm the company's business, financial condition, operating results, and/or cash flows.
- Furthermore, the company may be required to enter into license or cross-license agreements with others under which the company may be obligated to grant licenses or cross-licenses to the other party or parties under specified terms and conditions. Such license or cross-license agreements may result in the company being required to grant licenses or cross-licenses to third parties under specified terms and conditions, which could significantly harm the company's business, financial condition, operating results, and/or cash flows.
- Finally, the company may be required to enter into indemnification agreements with others under which the company may be obligated to indemnify the other party or parties against certain liabilities, damages, obligations, claims, suits, costs, expenses, fees, penalties, taxes, interest, fines,
